Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises
Published Time:
2024-09-09 17:47
Source:
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
The National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises honor is specifically established to encourage small and medium-sized enterprises to achieve development in four aspects: specialized operations, refined output, unique processes, and novel products. It aims to cultivate a group of "pioneer" enterprises focused on niche markets with strong innovation capabilities, high market share, mastery of key core technologies, and excellent quality and efficiency, thereby strengthening the real economy—particularly manufacturing—and enhancing the stability and competitiveness of industrial and supply chains.
Since its establishment, Jiangsu Vcare has been committed to pharmaceutical R&D and innovation, adhering to the "Specialized, Refined, Unique, Innovative" development path, and building a full-chain chemical drug R&D service technology platform. From front-end research, the company has constructed integrated drug R&D platforms including AI molecular generation, drug screening, crystal/salt form selection, and novel drug formulation, establishing core innovation capabilities in early-stage product development. Back-end development further incorporates advanced manufacturing technology platforms such as synthetic biology, enzyme catalysis engineering, and continuous flow engineering, supplemented by preparation/separation technologies and multi-chiral drug development strategies, building robust technical barriers for industrialization. In 2024, the company's revenue will exceed RMB 400 million.
Jiangsu Vcare will continue to uphold its core values of"The better Care, The better Medicines", strengthen its core competitiveness and technological innovation capabilities, and contribute to Chinese pharmaceutical innovation through scientific, conceptual, and management innovation, thereby supporting the "Healthy China" initiative.
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn